Related Experiment Video
Updated: Jun 25, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Global research trends in immunotherapy for non-small cell lung cancer patients with KRAS mutations: a bibliometric
1Department of Clinical Laboratory, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People's Hospital, Wuxi, Jiangsu, China.
Background:
Immunotherapy, frequently combined with conventional chemotherapy, is crucial for treating NSCLC. Kirsten rat sarcoma virus (KRAS) is a poor prognostic factor in patients with NSCLC, particularly lung adenocarcinoma, where binding of conventional inhibitors to mutated KRAS proteins is challenging. Field profiles, research hotspots, and prospects for immunotherapy for patients with NSCLC-carrying KRAS mutations were uncovered in this study.
Methods:
Microsoft Excel 2019, Bibliometrix, VOSviewer software, and Citespace were utilized to conduct a comprehensive scientometric analysis and understand a specific research field's knowledge base and frontiers aided by bibliometrics.
Results:
Between 2014 and 2023, 398 eligible documents in the English language were acquired using the WoSCC database, of which 113 and 285 were reviews and articles, respectively. The growth rate per year was 34.25 %. The most cited articles were from the United States, and China published the highest number of articles. Cancers was the journal, with increased publications in recent years. The keywords with the strongest citation bursts were analyzed using Citespace. "Immune checkpoint inhibitors," "co-occurring genomic alterations," and "KRAS" are among the research hotspots in this field.
Conclusion:
Using bibliometric and visual analyses, we examined immunotherapy for patients with KRAS-mutant NSCLC over the previous decade. The whole analysis showed a steady, quick increase in yearly publications in this area. Our findings will provide a roadmap for future research on the mechanisms of immunotherapy and immune checkpoint inhibitor action in treating KRAS-mutant NSCLC.
Insights
Immunotherapy shows promise for KRAS-mutant non-small cell lung cancer (NSCLC). This study analyzes a decade of research, highlighting immune checkpoint inhibitors and genomic alterations as key areas for future investigation.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) treatment often involves immunotherapy and chemotherapy.
- KRAS mutations are a poor prognostic indicator in NSCLC, complicating targeted therapy.
- Understanding immunotherapy's role in KRAS-mutant NSCLC is critical.
Approach:
- A bibliometric analysis of 398 English-language documents from 2014-2023 was performed.
- VOSviewer and Citespace software were used for scientometric analysis.
- Research trends, hotspots, and citation bursts were identified.
Key Points:
- Annual publications on immunotherapy for KRAS-mutant NSCLC grew by 34.25% yearly.
- The United States led in highly cited articles, while China published the most.
- Key research hotspots include immune checkpoint inhibitors and co-occurring genomic alterations.
Conclusions:
- Bibliometric analysis reveals a decade of increasing research in immunotherapy for KRAS-mutant NSCLC.
- This study provides a roadmap for future research directions.
- Findings will guide investigations into immunotherapy mechanisms and immune checkpoint inhibitor efficacy in KRAS-mutant NSCLC.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...